Canal ionique

Amiodarone a class III anti-arrhythmic agent, used to treat and prevent certain types of irregular heartbeats. It is a competitor for natural ligands of alpha and beta adrenergic receptors, muscarinic acetylcholine receptors, histamine H1 receptors, and serotonin 5HT2A/5HT2C receptors. Amiodarone has been shown to reduce the number of atrial and ventricular arrhythmias in patients with structural heart disease, and has been used to treat atrial fibrillation, ventricular tachycardia, and Wolff-Parkinson-White Syndrome. It has also been used in the prevention of myocardial infarcts due to its ability to modify blood pressure and maintain cardiac function. In addition, amiodarone inhibits prostaglandin synthesis by inhibiting cyclooxygenase enzymes. This prevents inflammation in the gastrointestinal tract and reduces bowel disease symptoms such as cramping or diarrhea.

Nateglinide is used to treat type 2 diabetes mellitus as an oral hypoglycemic, insulinotropic agent. It is a blocker of ATP-dependent potassium channels and works by increasing the body's production of insulin, which lowers blood glucose levels. Nateglinide has been shown to be effective in reducing postprandial blood glucose levels in patients with type 2 diabetes who have not responded well to other treatments. The effects of nateglinide are reversible.

Flumazenil is a drug that reverses the effects of benzodiazepines, such as diazepam, lorazepam, and midazolam. It binds to the α1 subunit of the GABA receptor and prevents it from opening. Flumazenil is a benzodiazepine antagonist.

NBQX is a competitive antagonist of ionotropic glutamate receptors of AMPA and kainate subfamilies. It has been reported anti-convulsant activity in seizures models induced by electrostimulation, drugs or genetic predisposition. It has also exhibited pro-convulsant effects in Theiler's murine encephalomyelitis virus-induced (TMEV) seizure model.

Nicorandil is an ATP-dependent potassium channel activator. It activates mitochondrial ATP-dependent potassium (KATP) channels and inhibits the TLR4/MyD88/NF-κB/NLRP3 pathway, which reduces myocardial infarction-induced pyroptosis. Pyroptosis is an inflammatory cell death process that regulates cardiomyocyte loss after myocardial infarction. These findings suggest that nicorandil may be a potential therapy for ischemic heart disease due to its cardioprotective effects.

Voltage-dependent K+ channel opener; insulinotropic sulfonylurea receptor ligand

Clinidipine is a dihydropyridine calcium channel blocker that is used to treat hypertension. This drug acts on L-type calcium channels of blood vessels by blocking calcium and suppressing the contraction of blood vessels, thereby reducing blood pressure. . Cilnidipine also shows activity against N-type calcium channels.